Medicare
Annual Medicare Expense for Anti-VEGF Injections Tops $4 Billion, Study Finds
A significant rise ($1.5 billion more per year) can be attributed to greater uptake of aflibercept by retina specialists. Regional differences reflect local variation in disease burden.
02/21/2024
Age-related Eye Diseases Higher in Prevalence, Incidence Over 15 Years
While the trends reported represent small changes, due to the size of the US Medicare beneficiary population these differences equate to a large number of individuals and considerable economic cost.
07/26/2023
Lack of Eye Care Access in US Reflects Socioeconomic Trends
Patients with Medicare in areas that were rural, had lower household incomes or higher unemployment rates did not make significant use of available services.
05/30/2023
Upcoming Events
May 17-19, 2024
June 4, 2024
Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition
Location: Virtual
Presenters: Karl G. Stonecipher, MD, and Jessica Steen, OD
Webinar: 8:00pm ET
Sponsored by Bausch + Lomb
September 8, 2024
Ocular Surface Symposium
Location: Renaissance Chicago Downtown Hotel
Presenter: Paul Karpecki, OD
